PhytoHealth Corp. (4108)

Overview

PhytoHealth Corporation is a prominent entity in Taiwan that delves into the research, development, manufacturing, and sales of a diverse range of products spanning pharmaceutical drugs, cosmetics, Class B medicines, and dietary supplements. Established in 1998 and headquartered in Taipei, Taiwan, the company has crafted a significant presence across three main segments: Pharmaceutical Drugs and Dietary Supplement, Medical Diagnostic Products, and Precision Medical Equipment. Each segment focuses on delivering innovative solutions catered to enhancing health and medical diagnostics. With its commitment to advancing medical science and healthcare, PhytoHealth Corporation invests heavily in research and development, ensuring their product offerings are not only advanced but also meet the rigorous needs of their clients and the healthcare industry.

Products and Services

• Pharmaceutical Drugs and Dietary Supplement

  This segment stands at the core of PhytoHealth Corporation's operations, specializing in the manufacture and sale of Chinese medicines and new pharmaceutical products. It reflects the company's dedication to blending traditional therapies with modern pharmaceutical advancements to create effective treatments.

• Medical Diagnostic Products

  Focuses on the development and sales of smart medical imaging diagnostic products devices. These innovative products aim to revolutionize medical diagnostics through advanced technology, improving the accuracy and efficiency of medical diagnostics processes.

• Precision Medical Equipment

  Engages in the extensive research, development, manufacturing, and sale of ultrasonic probes. This segment highlights PhytoHealth Corporation's commitment to precision in medical treatments, ensuring that healthcare providers have access to high-quality equipment for accurate diagnosis and treatment.

• PHN031, PHN033, PHN016, and PHN017

  PhytoHealth Corporation is developing a robust pipeline of pharmaceutical drugs aimed at treating various medical conditions. PHN031 and PHN033 have completed Phase II clinical trials for osteoporosis and diabetic nephropathy, respectively. Meanwhile, PHN016, targeting cancer treatment, and PHN017, aimed at treating severe infection-induced cytokine storm, are making significant progress in their respective clinical trials.

• PG2 Lyophilized Injection and Capsules

  Among its product offerings, the PG2 Lyophilized injection stands out for its application in the treatment of cancer-related fatigue, highlighting the company's focus on addressing the side effects of cancer treatment. Additionally, the company offers capsules designed to supplement its pharmaceutical offerings, potentially enhancing patient care and treatment outcomes.

• Collaboration with Indena S.P.A

  PhytoHealth Corporation has entered into a collaboration agreement with Indena S.P.A, focusing on the development of botanical extracts. This partnership underscores the company's interest in exploring natural remedies and integrating them into their research and development process for new pharmaceutical products.